Dr. Marcel Doerflinger

The Walter and Eliza Hall Institute of Medical Research

biography

Dr Marcel Doerflinger is a Bellberry-Viertel Senior Medical Research Fellow and Laboratory Head in the Infection and Global Health Division at the Walter and Eliza Hall Institute of Medical Research (WEHI), Melbourne, Australia. His research focuses on understanding the regulatory processes of programmed cell death and inflammation at the host-pathogen interface of infection. His team’s projects leverage basic discovery biology and sophisticated preclinical animal models of disease — including in high-containment PC3 facilities — to develop novel therapeutic strategies with translational outcomes for high-impact infections including Tuberculosis, HIV, HTLV-1, and acute and long COVID.

Marcel has published first and senior-author manuscripts in prestigious journals including Cell, Immunity, PNAS, and Nature Communications, and has secured over $10 million AUD in competitive research funding. His collaborative network spans institutes across Australia, Japan, Europe, and the United States, and the preclinical disease models developed in his laboratory have supported the initiation of two international clinical trials, enabled two patents, and underpinned a diverse pipeline of therapeutic approaches including small molecules, nanobodies, and lipid nanoparticle RNA therapeutics.

Title

Mouse models for therapeutic discovery at the host pathogen interface

abstract

Programmed cell death and inflammation critically shape immunity to pathogens, yet their dysregulation drives immunopathology across a broad spectrum of infectious diseases. Understanding how pathogens subvert these host cell signalling pathways — and how to exploit this knowledge therapeutically — requires robust, physiologically relevant in vivo platforms. Our laboratory has developed a suite of complementary mouse model systems, operated within BSL2 and BSL3 high-containment facilities, that allow therapeutic discovery and preclinical evaluation across multiple infectious diseases of global health significance.

In vivo screens using gene-targeted animals lacking key regulators of programmed cell death and inflammation have revealed that caspase-8 plays a central role in driving pathology during severe SARS-CoV-2 infection and is also key regulator of inflammatory disease in dengue virus infection — identifying the caspase-8 signaling axis as relevant and therapeutically tractable host target. Our P21 mouse-adapted SARS-CoV-2 strain further recapitulates key features of long COVID including persistent lung inflammation, neuroinflammation, neurogeneneration, and gut dysbiosis, providing a unique platform to understand drivers of long COVID pathology and to evaluate emerging PASC interventions. Additionally, we have established humanised mouse models that allow preclinical studies for strictly human-tropic pathogens. Using this platform, we identified that targeting pro-survival pathways using SMAC and BH3 mimetics can eliminate infected cells and translated towards curative strategies for HIV and HTLV-1.

This integrated in vivo approach – combining genetic dissection, physiologically relevant infection models, multi-omics readouts, and therapeutic screening – supports pandemic preparedness and the development of host-directed therapies against current and emerging infectious disease threats.